What is Losartana Potássica + HCT Gen.Legrand?
Losartana Potássica + HCT Gen.Legrand contains a combination of Losartana Potássica + HCT Gen.Legrand. Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention. Losartan (Losartana Potássica + HCT Gen.Legrand) is an angiotensin II receptor antagonist. Losartan (Losartana Potássica + HCT Gen.Legrand) keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Losartana Potássica + HCT Gen.Legrand is used to treat high blood pressure (hypertension). It is also used to lower the risk of stroke in certain people with heart disease.
Losartana Potássica + HCT Gen.Legrand may also be used for purposes not listed in this medication guide.
Losartana Potássica + HCT Gen.Legrand indications
Hypertension
Losartana Potássica + HCT Gen.Legrand® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan (Losartana Potássica + HCT Gen.Legrand) and Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand).
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
Losartana Potássica + HCT Gen.Legrand may be administered with other antihypertensive agents.
Hypertensive Patients With Left Ventricular Hypertrophy
Losartana Potássica + HCT Gen.Legrand is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.
How should I use Losartana Potássica + HCT Gen.Legrand?
Use Losartana Potássica + HCT Gen.Legrand as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Losartana Potássica + HCT Gen.Legrand. Talk to your pharmacist if you have questions about this information.
- Take Losartana Potássica + HCT Gen.Legrand by mouth with or without food.
- Drinking extra fluids while you are taking Losartana Potássica + HCT Gen.Legrand is recommended. Check with your doctor for instructions.
- Losartana Potássica + HCT Gen.Legrand may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.
- If you take cholestyramine or colestipol, ask your doctor or pharmacist how to take it with Losartana Potássica + HCT Gen.Legrand.
- Continue to take Losartana Potássica + HCT Gen.Legrand even if you feel well. Do not miss any doses.
- If you miss a dose of Losartana Potássica + HCT Gen.Legrand, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Losartana Potássica + HCT Gen.Legrand.
Uses of Losartana Potássica + HCT Gen.Legrand in details
Use: Labeled Indications
Hypertension: Management of hypertension.
Hypertension with left ventricular hypertrophy: To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH). Evidence suggests that this benefit does not apply to black patients.
Losartana Potássica + HCT Gen.Legrand description
Each tablet contains Losartan (Losartana Potássica + HCT Gen.Legrand) potassium 50 or 100 mg and Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) 12.5 mg.
Losartan (Losartana Potássica + HCT Gen.Legrand) Potassium: Losartan (Losartana Potássica + HCT Gen.Legrand) potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losartan (Losartana Potássica + HCT Gen.Legrand) potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents eg, acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losartan (Losartana Potássica + HCT Gen.Legrand).
Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand): Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.
Its empirical formula is C7H8ClN3O4S2.
It is a white, or practically white, crystalline powder with a molecular weight of 297.74, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.
Losartana Potássica + HCT Gen.Legrand dosage
Hypertension
The usual starting dose of Losartana Potássica + HCT Gen.Legrand is 50/12.5 (Losartan (Losartana Potássica + HCT Gen.Legrand) 50 mg/Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losartana Potássica + HCT Gen.Legrand) 100 mg/Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) 25 mg) once daily as needed to control blood pressure.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartana Potássica + HCT Gen.Legrand) 50 mg monotherapy with Losartana Potássica + HCT Gen.Legrand 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losartana Potássica + HCT Gen.Legrand 50/12.5 once daily or one tablet of Losartana Potássica + HCT Gen.Legrand 100/25 once daily.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartana Potássica + HCT Gen.Legrand) 100 mg monotherapy with Losartana Potássica + HCT Gen.Legrand 100/12.5 (Losartan (Losartana Potássica + HCT Gen.Legrand) 100 mg/Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartana Potássica + HCT Gen.Legrand 50/12.5 once daily or one tablet of Losartana Potássica + HCT Gen.Legrand 100/25 once daily.
Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losartana Potássica + HCT Gen.Legrand 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losartana Potássica + HCT Gen.Legrand 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartana Potássica + HCT Gen.Legrand 50/12.5 once daily or one tablet of Losartana Potássica + HCT Gen.Legrand 100/25 once daily.
Hypertensive Patients with Left Ventricular Hypertrophy
In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losartana Potássica + HCT Gen.Legrand) potassium, initiate treatment with Losartana Potássica + HCT Gen.Legrand 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losartana Potássica + HCT Gen.Legrand 100/12.5, followed by Losartana Potássica + HCT Gen.Legrand 100/25. For further blood pressure reduction add other antihypertensives.
Losartana Potássica + HCT Gen.Legrand interactions
See also:
What other drugs will affect Losartana Potássica + HCT Gen.Legrand?
Agents Increasing Serum Potassium
Coadministration of Losartan (Losartana Potássica + HCT Gen.Legrand) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losartana Potássica + HCT Gen.Legrand and lithium.
Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors
Losartan (Losartana Potássica + HCT Gen.Legrand) Potassium
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losartana Potássica + HCT Gen.Legrand)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losartana Potássica + HCT Gen.Legrand) and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losartana Potássica + HCT Gen.Legrand), may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand)
The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartana Potássica + HCT Gen.Legrand and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losartana Potássica + HCT Gen.Legrand), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand), Losartan (Losartana Potássica + HCT Gen.Legrand), and NSAID therapy.
Dual Blockade Of The Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losartana Potássica + HCT Gen.Legrand) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losartana Potássica + HCT Gen.Legrand) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
Closely monitor blood pressure, renal function, and electrolytes in patients on Losartana Potássica + HCT Gen.Legrand and other agents that affect the RAS.
Do not coadminister aliskiren with Losartana Potássica + HCT Gen.Legrand in patients with diabetes. Avoid use of aliskiren with Losartana Potássica + HCT Gen.Legrand in patients with renal impairment (GFR < 60 mL/min).
The Use Of Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) With Other Drugs
When administered concurrently, the following drugs may interact with thiazide diuretics :
Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.
Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) and the resin such that Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
Losartana Potássica + HCT Gen.Legrand side effects
See also:
What are the possible side effects of Losartana Potássica + HCT Gen.Legrand?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Losartan (Losartana Potássica + HCT Gen.Legrand) potassium-Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) has been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. Most adverse reactions have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse events was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, adverse reactions occurring in greater than 2% of subjects treated with Losartan (Losartana Potássica + HCT Gen.Legrand)-Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) and at a greater rate than placebo were: back pain (2.1% vs 0.6%), dizziness (5.7% vs 2.9%), and upper respiratory infection (6.1% vs 4.6%).
The following additional adverse reactions have been reported in clinical trials with Losartana Potássica + HCT Gen.Legrand and/or the individual components:
Blood and the lymphatic system disorders: Anemia, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis.
Metabolism and nutrition disorders: Anorexia, hyperglycemia, hyperuricemia, electrolyte imbalance including hyponatremia and hypokalemia.
Psychiatric disorders: Insomnia, restlessness.
Nervous system disorders: Dysgeusia, headache, migraine, paraesthesias.
Eye disorders: Xanthopsia, transient blurred vision.
Cardiac disorders: Palpitation, tachycardia.
Vascular disorders: Dose-related orthostatic effects, necrotizing angiitis (vasculitis, cutaneous vasculitis).
Respiratory, thoracic and mediastinal disorders: Nasal congestion, pharyngitis, sinus disorder, respiratory distress (including pneumonitis and pulmonary edema).
Gastrointestinal disorders: Dyspepsia, abdominal pain, gastric irritation, cramping, diarrhea, constipation, nausea, vomiting, pancreatitis, sialoadenitis.
Hepato-biliary disorders: Jaundice (intrahepatic cholestatic jaundice).
Skin and subcutaneous tissue disorders: Rash, pruritus, purpura, toxic epidermal necrolysis, urticaria, photosensitivity, cutaneous lupus erythematosus.
Musculoskeletal and connective tissue disorders: Muscle cramps, muscle spasm, myalgia, arthralgia.
Renal and urinary disorders: Glycosuria, renal dysfunction, interstitial nephritis, renal failure.
Reproductive system and breast disorders: Erectile dysfunction/impotence.
General disorders and administration site conditions: Chest pain, edema/swelling, malaise, fever, weakness.
Investigations: Liver function abnormalities.
Cough
Persistent dry cough has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of Losartan (Losartana Potássica + HCT Gen.Legrand) on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to Losartan (Losartana Potássica + HCT Gen.Legrand) 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below.
| |||
| Study 1* | HCTZ | Losartan (Losartana Potássica + HCT Gen.Legrand) | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2† | Placebo | Losartan (Losartana Potássica + HCT Gen.Legrand) | Lisinopril |
| Cough | 35% | 29% | 62% |
These studies demonstrate that the incidence of cough associated with Losartan (Losartana Potássica + HCT Gen.Legrand) therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand) or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of Losartan (Losartana Potássica + HCT Gen.Legrand) in postmarketing experience.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Losartana Potássica + HCT Gen.Legrand. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Digestive: Hepatitis has been reported rarely in patients treated with Losartan (Losartana Potássica + HCT Gen.Legrand).
Hematologic: Thrombocytopenia.
Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with Losartan (Losartana Potássica + HCT Gen.Legrand); some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schönlein purpura, has been reported with Losartan (Losartana Potássica + HCT Gen.Legrand). Anaphylactic reactions have been reported.
Musculoskeletal: rhabdomyolysis
Skin: Erythroderma
Losartana Potássica + HCT Gen.Legrand contraindications
See also:
What is the most important information I should know about Losartana Potássica + HCT Gen.Legrand?
Hypersensitivity to Losartan (Losartana Potássica + HCT Gen.Legrand), sulphonamide-derived substances (as Hydrochlorothiazide (Losartana Potássica + HCT Gen.Legrand)) or to any of the excipients of Losartana Potássica + HCT Gen.Legrand.
Therapy resistant hypokalemia or hypercalcemia; severe hepatic impairment; cholestasis and biliary obstructive disorders; refractory hyponatremia; symptomatic hyperuricemia/gout; 2nd and 3rd trimester of pregnancy; lactation; severe renal impairment (ie, creatinine clearance <30 mL/min); anuria.
Excipient: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Losartana Potássica + HCT Gen.Legrand.
Use in lactation: It is not known whether Losartan (Losartana Potássica + HCT Gen.Legrand) is excreted in human milk. However, Losartan (Losartana Potássica + HCT Gen.Legrand) is excreted in the milk of lactating rats. Because no information is available regarding the use of Losartan (Losartana Potássica + HCT Gen.Legrand) during breastfeeding, Losartan (Losartana Potássica + HCT Gen.Legrand) is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Thiazides pass into human milk and may inhibit lactation. Because of the potential for adverse effects on the nursing infant, Losartan (Losartana Potássica + HCT Gen.Legrand)/HCTZ is contraindicated during breastfeeding.
Active ingredient matches for Losartana Potássica + HCT Gen.Legrand:
Hydrochlorothiazide/Losartan in Brazil.
List of Losartana Potássica + HCT Gen.Legrand substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Losartana Potássica + HCT Pharlab (Brazil) | |
| Losartankalium/HCT CF (Netherlands) | |
| Losartankalium/HCT Jubilant (Netherlands) | |
| Losartankalium/HCT PCH (Netherlands) | |
| Losartankalium/HCT Ranbaxy (Netherlands) | |
| Losartankalium/HCT ratiopharm (Netherlands) | |
| Losartankalium/HCT Teva (Netherlands) | |
| Losartankalium/HCT Xiromed (Netherlands) | |
| Losartankalium/hydrochloorthiazide A (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Apotex (Netherlands) | |
| Losartankalium/hydrochloorthiazide Auro (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Bluefish (Netherlands) | |
| Losartankalium/hydrochloorthiazide Farmaprojects (Netherlands) | |
| Losartankalium/hydrochloorthiazide IPCA (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Mylan (Netherlands) | |
| Losartankalium/hydrochlorthiazid Actavis (Denmark) | |
| Losartankalium/hydrochlorthiazid Amneal (Denmark) | |
| Losartankalium/hydrochlorthiazid Krka (Denmark) | |
| Losartankalium/Hydrochlorthiazid Medical Valley (Denmark) | |
| Losartankalium/hydrochlorthiazid Teva (Denmark) | |
| Losartar-H (India) | |
| Losartar-H Losartan K , Hydrochlorothiazide TAB / 10 (Shrrishti HC) | $ 0.60 |
| 10's (Shrrishti HC) | $ 0.60 |
| LOSARTAR-H tab 10's (Shrrishti HC) | $ 0.60 |
| Losartas HT (Peru) | |
| Losartas HT Hydrochlorothiazide 12.5mg, Losartan K 50mg TAB / 7 | $ 0.69 |
| Losartas HT Tablet (Intas Pharmaceuticals Ltd) | $ 0.11 |
| Losarteg HCT (El Salvador) | |
| Losartic HC (Slovenia) | |
| Losartic Plus (Croatia (Hrvatska), Serbia) | |
| Losartil-Plus (Turkey) | |
| Losasis-H | |
| Losasis-H 50mg/12.5mg Tablet (CHS Formulations) | $ 0.08 |
| Losastal-H Tablet | |
| Losastal-H Tablet (Stallion Laboratories Pvt Ltd) | $ 0.08 |
| LOSASUN HT | |
| LOSASUN HT TABLET 1 strip / 10 tablets each (Sunij Pharma Pvt Ltd) | $ 0.35 |
| LOSATAN H | |
| LOSATAN H TABLET 1 strip / 10 tablets each (Biochem Pharmaceutical Industries) | $ 0.60 |
| Losatan Hz (Bangladesh) | |
| LOSATEC H | |
| LOSATEC H 50 MG/12.5 MG TABLET 1 strip / 10 tablets each (RPG Life Sciences Ltd) | $ 1.00 |
| Losatec-H (India) | |
| Losatec-H Capsule/ Tablet / 12.5mg-50mg / 10 units (RPG LS) | $ 0.64 |
| Losatec-H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 10 (RPG LS) | $ 0.83 |
| 10's (RPG LS) | $ 0.83 |
| LOSATEC-H tab 10's (RPG LS) | $ 0.83 |
| Losatrix Comp (Finland, Sweden) | |
| LOSATRUST H | |
| LOSATRUST H TABLET 1 strip / 10 tablets each (Centaur Pharmaceuticals Pvt Ltd) | $ 0.76 |
| Losatrust-H (India) | |
| Losatrust-H Capsule/ Tablet / 12.5mg-50mg / 10 units (Centaur (Sankalp)) | $ 0.43 |
See 1294 substitutes for Losartana Potássica + HCT Gen.Legrand | |
References
- DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losartana Potássica + HCT Gen.Legrand are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losartana Potássica + HCT Gen.Legrand. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
